Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Eurasia

The patent to be granted by the Eurasian Patent Office is valid until 2035. It primarily protects the use of a GAD autoantigen to treat or prevent autoimmune diabetes in individuals carrying the HLA DR3-DQ2 gene. GAD is the active component in the antigen-specific immunotherapy Diamyd[®] that is being evaluated in the confirmatory Phase III trial DIAGNODE-3.The countries included in the Eurasian cooperation are Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan and Turkmenistan. HLA DR3-DQ2, associated with autoimmunity against GAD, represents one of the most common